Brokerages Expect Fate Therapeutics Inc (FATE) Will Announce Quarterly Sales of $1.85 Million
Equities research analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will announce sales of $1.85 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Fate Therapeutics’ earnings, with estimates ranging from $1.03 million to $2.13 million. Fate Therapeutics reported sales of $1.03 million during the same quarter last year, which indicates a positive year-over-year growth rate of 79.6%. The firm is expected to issue its next quarterly earnings results on Wednesday, November 7th.
On average, analysts expect that Fate Therapeutics will report full year sales of $4.74 million for the current fiscal year, with estimates ranging from $4.00 million to $5.21 million. For the next fiscal year, analysts expect that the business will post sales of $2.54 million per share, with estimates ranging from $1.03 million to $4.11 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Fate Therapeutics.
Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 1,387.53% and a negative return on equity of 95.07%. The company’s revenue for the quarter was up .0% on a year-over-year basis.
NASDAQ:FATE traded down $0.13 during mid-day trading on Friday, reaching $11.63. The stock had a trading volume of 357,400 shares, compared to its average volume of 611,827. Fate Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $14.45. The company has a market capitalization of $632.48 million, a P/E ratio of -11.40 and a beta of 1.76. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.92 and a current ratio of 4.92.
Large investors have recently added to or reduced their stakes in the stock. First Mercantile Trust Co. increased its holdings in Fate Therapeutics by 113.7% in the second quarter. First Mercantile Trust Co. now owns 12,899 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 6,863 shares during the last quarter. Alps Advisors Inc. bought a new stake in Fate Therapeutics during the second quarter worth approximately $870,000. Trexquant Investment LP bought a new stake in Fate Therapeutics during the first quarter worth approximately $179,000. Schwab Charles Investment Management Inc. boosted its position in Fate Therapeutics by 47.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 97,500 shares of the biopharmaceutical company’s stock worth $952,000 after purchasing an additional 31,500 shares during the period. Finally, Boston Advisors LLC boosted its position in Fate Therapeutics by 12.8% during the second quarter. Boston Advisors LLC now owns 58,030 shares of the biopharmaceutical company’s stock worth $658,000 after purchasing an additional 6,570 shares during the period. Hedge funds and other institutional investors own 80.62% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.
Read More: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.